- Home
- VNRX vs INZY Comparison
VNRX vs INZY Comparison
Compare VNRX & INZY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNRX
- INZY
- Stock Information
- Founded
- VNRX N/A
- INZY 2015
- Country
- VNRX United States
- INZY United States
- Employees
- VNRX N/A
- INZY N/A
- Industry
- VNRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- INZY Biotechnology: Pharmaceutical Preparations
- Sector
- VNRX Health Care
- INZY Health Care
- Exchange
- VNRX Nasdaq
- INZY Nasdaq
- Market Cap
- VNRX 58.6M
- INZY 64.9M
- IPO Year
- VNRX N/A
- INZY 2020
- Fundamental
- Price
- VNRX $0.55
- INZY $0.92
- Analyst Decision
- VNRX Strong Buy
- INZY Strong Buy
- Analyst Count
- VNRX 4
- INZY 10
- Target Price
- VNRX $4.17
- INZY $16.90
- AVG Volume (30 Days)
- VNRX 129.2K
- INZY 522.9K
- Earning Date
- VNRX 05-12-2025
- INZY 03-10-2025
- Dividend Yield
- VNRX N/A
- INZY N/A
- EPS Growth
- VNRX N/A
- INZY N/A
- EPS
- VNRX N/A
- INZY N/A
- Revenue
- VNRX $1,285,827.00
- INZY N/A
- Revenue This Year
- VNRX $71,446.31
- INZY N/A
- Revenue Next Year
- VNRX N/A
- INZY N/A
- P/E Ratio
- VNRX N/A
- INZY N/A
- Revenue Growth
- VNRX 97.50
- INZY N/A
- 52 Week Low
- VNRX $0.43
- INZY $0.91
- 52 Week High
- VNRX $1.02
- INZY $7.80
- Technical
- Relative Strength Index (RSI)
- VNRX 46.10
- INZY 32.69
- Support Level
- VNRX $0.51
- INZY $0.94
- Resistance Level
- VNRX $0.57
- INZY $1.05
- Average True Range (ATR)
- VNRX 0.04
- INZY 0.08
- MACD
- VNRX -0.00
- INZY 0.01
- Stochastic Oscillator
- VNRX 40.00
- INZY 5.37
About VNRX VolitionRX Limited
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
About INZY Inozyme Pharma Inc.
Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.